Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP) Academic Article uri icon

Overview

MeSH Major

  • Purpura, Thrombocytopenic, Idiopathic
  • Quality of Life
  • Receptors, Fc
  • Recombinant Fusion Proteins
  • Thrombopoietin

abstract

  • Romiplostim significantly reduced parental burden in this study. Whether the same and/or additional improvements in HRQoL would be demonstrated by a larger, longer study of romiplostim-treated children with ITP remains to be determined. Pediatr Blood Cancer 2012; 58: 395-398. © 2011 Wiley Periodicals, Inc.

publication date

  • March 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/pbc.23312

PubMed ID

  • 21910213

Additional Document Info

start page

  • 395

end page

  • 8

volume

  • 58

number

  • 3